JHJonathan L. Haines

Jonathan L. Haines

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jonathan L. Haines has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Shared Genetic Architecture Between Kidney Function and Alzheimer Disease Across Ancestries

    by Diya Yang, Yihe Yang, Nicholas R. Ray, Mengxuan Li, Penelope Benchek, Dana C. Crawford, John F. O’Toole, John R. Sedor, Christiane Reitz, Audrey Lynn, et al.

    Epidemiological studies have consistently shown that chronic kidney disease is associated with increased Alzheimer disease risk. However, the underlying genetic architecture connecting these two conditions remains largely unexplored beyond genome-wide correlation analyses. Here, we conducted the first comprehensive, multi-ancestry, large-scale genetic investigation to identify shared genetic components between kidney function and Alzheimer disease. We leveraged large-scale genome-wide association study summary statistics for estimated glomerular filtration rate (N≈1.5 million European, N≈145,000 African ancestry) and late-onset Alzheimer disease (N=63,926 and N=398,058 in two European cohorts; N=9,168 in African ancestry) corrected for competing risk bias. We deployed a novel analytical framework integrating linkage disequilibrium score regression and polygenic risk score analysis, local analysis of [co]variant association, conjunctional false discovery rate analysis with Bayesian colocalization and fine-mapping, and bidirectional cis-Mendelian randomization to identify vertical pleiotropy. Despite the absence of genome-wide genetic correlation (r g ≈ 0, p > 0.1), local genetic analysis uncovered striking regional heterogeneity. Sixteen pleiotropic loci were identified in individuals of European ancestry (conjunctional false discovery rate < 0.05), including APOE , PICALM , SPI1 , and EFTUD1 , alongside 15 loci with significant local genetic correlations. Fine-mapping revealed that most pleiotropic loci harbored distinct causal variants for kidney function and Alzheimer disease, indicating horizontal pleiotropy. An APOE ε4-defining allele (rs429358) was the sole variant with shared causality across both traits. We identified vertical pleiotropy using cis-Mendelian randomization at the PICALM and EFTUD1 loci, providing evidence that kidney function-related genetic variants can causally affect Alzheimer disease risk at specific genomic loci. In contrast, loci such as CD2AP , MAT1A , and SYMPK demonstrated horizontal pleiotropy, reflecting shared upstream biological pathways rather than direct causal mediation. Notably, APOE was the only pleiotropic locus shared between European and African ancestry groups, underscoring marked ancestry-specific genetic architectures with critical implications for risk prediction and therapeutic translation. Alzheimer disease and kidney function share genetic components at specific loci rather than genome-wide, with mixed directional effects and horizontal pleiotropy explaining the absent global correlation despite strong local signals. At a subset of loci, we identified directional effects linking kidney genetic determinants to Alzheimer disease risk using cis-Mendelian randomization, supporting a complex kidney–brain genetic axis. Most overlap reflects horizontal pleiotropy, with limited loci showing vertical pleiotropy. APOE was the only shared locus across ancestries, underscoring ancestry-specific architectures with implications for risk prediction. The multi-scale approach used here also provides a methodological framework for dissecting complex disease relationships missed by traditional genome-wide analyses.

  • Open Access

    Rare coding variants from ADSP R5 whole-genome sequencing implicate novel genes in Alzheimer’s disease

    by Wan-Ping Lee, Hui Wang, Yuk Yee Leung, Po-Liang Cheng, Wendi Zheng, Otto Valladares, Wei-Hsuan Chung, Amanda Kuzma, Adam Naj, Badri Vardarajan, et al.

    The Alzheimer’s Disease Sequencing Project (ADSP) Release 5 provides whole-genome sequencing data from 58,507 individuals across diverse ancestries to discover rare coding variants and genes associated with Alzheimer’s disease (AD) and AD-related traits. Gene-based aggregation tests identified 40 genes surpassing a Bonferroni-corrected gene-wide significance threshold, including established loci (TREM2, PSEN1) and putative novel candidates. In replication analyses, 21 genes showed nominal support in UK Biobank and Alzheimer’s Disease Genetics Consortium (ADGC) cohorts, with eight genes (TREM2, ACADS, MFSD12, NUP210L, PIEZO2, PSEN1, SMURF2, AKAP13) supported under identical masks. Carrier-based analyses of AD-related traits linked rare variants to age at onset, neuropathology, cognition, and cerebrospinal fluid biomarkers (Aβ42, total tau, pTau181). Furthermore, we observed that AD-enriched variants were more likely to be ancestry-concentrated, and coalescent analyses indicated that AD risk alleles are younger than background variants. Together, these findings provide a multi-ancestry rare-variant resource for AD gene discovery.


  • Open Access

    Combining xQTL and genome-wide association studies from diverse populations improves druggable gene discovery

    by Noah Lorincz-Comi, Wenqiang Song, Xin Chen, Isabela Rivera Paz, Yuan Hou, Yadi Zhou, Jielin Xu, William Martin, John Barnard, Andrew A. Pieper, et al.

    Repurposing existing medicines to target disease-associated genes represents a promising strategy for developing effective treatments for complex diseases. However, progress has been hindered by a lack of viable candidate drug targets identified through genome-wide association studies. Gene-based association tests provide a more powerful alternative to traditional SNP-based methods, yet current approaches often fail to leverage shared heritability across populations and to effectively integrate functional genomic data. To address these challenges, we develop GenT and its various extensions, comprising a framework of gene-based tests utilizing summary-level data from genome-wide association studies. Using GenT, we identify 16, 15, 35, and 83 candidate genes linked to Alzheimer’s disease, amyotrophic lateral sclerosis, major depression, and schizophrenia, respectively, not detected by Genome-Wide Association Studies (GWAS). Additionally, we use our multi-ancestry gene-based test (MuGenT) to identify 28 candidate genes associated with type 2 diabetes. By integrating brain expression and protein quantitative trait loci into our analysis, we identify 43 candidate genes associated with Alzheimer’s disease that have supporting xQTL evidence. We also perform experimental assays to demonstrate that the NTRK1 inhibitor GW441756 significantly reduces tau hyper-phosphorylation (including p-tau181 and p-tau217) in Alzheimer’s disease patient-derived iPSC neurons, providing mechanistic support for our predictions.


  • Open Access

    Country-level incidence of Alzheimer disease and related dementias is associated with increased omega-6-PUFA consumption

    by Timothy H. Ciesielski, Giuseppe Tosto, Razaq O. Durodoye, Farid Rajabli, Rufus O. Akinyemi, Goldie S. Byrd, William S. Bush, Brian W. Kunkle, Christiane Reitz, Jeffery M. Vance, et al.

    Background: Clinical and genetic studies have implicated lipid dysfunction in Alzheimer Disease (AD) pathogenesis. While the etiologic impact of lipid intake on individuals is receiving attention, the role of food systems in shaping community-level incidence remains uncharacterized. Methods: Mean country-level lipid intakes were compared to Age-Standardized Alzheimer-and-other-Dementia Incidence Rates (ASAIR) in 183 countries across all inhabited continents. Free-knot penalized spline regression and multivariable-adjusted linear regression, including a lag between intake and incidence, were used to assess the relationships between five lipid intakes and ASAIR. Validation was conducted using longitudinal within-country changes between 1990 and 2019. Results: Here we show that omega-6 Polyunsaturated-Fatty-Acid (omega-6) intake exhibits a positive linear relationship with ASAIR (multivariable-adjusted model: β = 2.44; 95%CI: 1.70, 3.19; p = 1.38 × 10−9). ASAIR also increases with saturated-fat, trans-fat, and dietary-cholesterol up to a threshold. The association between omega6-PUFA and ASAIR is confirmed using longitudinal intake changes. The scale of predicted benefits varies by country but, our results predict a 2 standard deviation decrease (−3.8% as a percent of daily energy intake) in omega-6 intake would reduce ASAIR by 8% in the US. This level of consumption has already been achieved in 20 countries. If our other findings are validated in future work, decreasing all four lipids could potentially yield large ASAIR reductions (in the US: a 35% decrease). Conclusions: Higher levels of omega-6 consumption associate with increased ASAIR. Thus, decreasing omega-6 consumption on the country-level may have substantial benefits in reducing the burden of dementia.


  • Open Access

    Combining xQTL and genome-wide association studies from ethnically diverse populations improves druggable gene discovery

    by Feixiong Cheng, Noah Lorincz-Comi, Wenqiang Song, Xin Chen, Isabela Rivera Paz, Yuan Hou, Yadi Zhou, Jielin Xu, William Martin, John Barnard, et al.

    Repurposing existing medicines to target disease-associated genes represents a promising strategy for developing new treatments for complex diseases. However, progress has been hindered by a lack of viable candidate drug targets identified through genome-wide association studies (GWAS). Gene-based association tests provide a more powerful alternative to traditional single nucleotide polymorphism (SNP)-based methods, yet current approaches often fail to leverage shared heritability across populations and to effectively integrate functional genomic data. To address these challenges, we developed GenT and its various extensions, comprising a framework of gene-based tests utilizing summary-level GWAS data. Using GenT, we identified 16, 15, 35, and 83 druggable genes linked to Alzheimer’s disease (AD), amyotrophic lateral sclerosis, major depression, and schizophrenia, respectively. Additionally, our multi-ancestry gene-based test (MuGenT) uncovered 28 druggable genes associated with type 2 diabetes that previous trans-ancestry or ancestry-specific GWAS had missed. By integrating brain expression and protein quantitative trait loci (e/pQTLs) into our analysis, we identified 43 druggable genes (e.g., RIPK2, NTRK1, RIOK1) associated with AD that had supporting xQTL evidence. Notably, experimental assays demonstrated that the NTRK1 protein inhibitor GW441756 significantly reduced tau hyper-phosphorylation (including p-tau181 and p-tau217) in AD patient-derived iPSC neurons, thus providing mechanistic support for our predictions. Overall, our findings underscore the power of gene-based association testing as a strategic tool for informed drug target discovery and validation based on human genetic and genomic data for complex diseases.


  • Open Access

    Combining genetics with real-world patient data enables ancestry-specific target identification and drug discovery in Alzheimer’s disease

    by Feixiong Cheng, Yuan Hou, Pengyue Zhang, Yichen Li, Noah Lorincz-Comi, Fan Fan, Wenqiang Song, Xing Fang, Yunguang Qiu, Isabela Rivera Paz, et al.

    Although high-throughput DNA/RNA sequencing technologies have generated massive genetic and genomic data in human disease, these findings have not been translated into new patient treatments. To address this problem, we utilized Mendelian randomization (MR) and large patient-level genetic and functional genomic data to evaluate druggable targets using Alzheimer’s disease (AD) as a prototypical example. Specifically, we applied the genetic instruments from 9 expression quantitative trait loci (eQTL) and 3 protein quantitative trait loci (pQTL) datasets across five human brain regions from three human brain biobanks and performed MR in 7 genome-wide association study (GWAS) datasets of European ancestry (EA) and African ancestry (AA), with AD cases and controls. We identified 19 drug targets, including the inflammatory target of epoxide hydrolase 2 (EPHX2) as a potent AD target. We demonstrated that a genome-wide significant and protective variant of p.Arg287Gln in EPHX2 (β = -0.096, PGWAS = 1.08 × 10-11) significantly reduced level of phosphorylated-tau (p-tau181) and the ratio of p-tau181/total tau and increased neuron clump size in patient induced Pluripotent Stem Cells (iPSC)-derived neurons, mechanistically supporting MR results. Pharmacologic inhibition of EPHX2 significantly improved cognitive behaviors in two AD transgenic rodent models (5xFAD and TgF344-AD). We further identified that 12 drugs (i.e., trazodone [ADRA1A] and baclofen [GABBR1]) harboring MR-supported targets are significantly associated with reduced incidence of AD in 111,680 mild cognitive impairment (MCI) patients from the Optum database. Using a new user active-comparator design, we found that usage of trazodone was significantly associated with 22% reduced incidence of AD (hazard ratio [HR] = 0.78, P=6.44x10-6) in people with MCI in the MarketScan database. In summary, combining genetics and real-world patient data identifies ancestry-specific therapeutic targets and medicines for AD and other neurodegenerative diseases if broadly applied.


  • Open Access

    Evaluating the association of APOE genotype and cognitive resilience in SuperAgers

    by Alaina Durant, Shubhabrata Mukherjee, Michael L. Lee, Seo-Eun Choi, Phoebe Scollard, Brandon S. Klinedinst, Emily H. Trittschuh, Jesse Mez, Lindsay A. Farrer, Katherine A. Gifford, et al.

    INTRODUCTION: “SuperAgers” are oldest-old adults (ages 80+) whose memory performance more closely resembles middle-aged adults. The present study examined APOE allele frequency in non-Hispanic Black (NHB) and non-Hispanic White (NHW) SuperAgers compared to controls and Alzheimer’s disease dementia cases. METHODS: In 18,080 participants from eight cohorts, harmonized clinical diagnostics and memory, executive function, and language domain scores were used to identify SuperAgers, cases, and controls across age-defined bins. RESULTS: NHW SuperAgers had significantly lower frequency of APOE- ε4 alleles and higher frequency of APOE -ε2 alleles compared to all cases and controls, including oldest-old controls. Similar patterns were found in a small yet substantial sample of NHB SuperAgers; however, not all comparisons with controls reached significance. DISCUSSION: We demonstrated strong evidence that APOE allele frequency relates to SuperAger status. Further research is needed with a larger sample of NHB SuperAgers to determine if mechanisms conferring resilience differ across race groups.


  • Open Access

    X‐chromosome-wide association study for Alzheimer’s disease

    by Julie Le Borgne, Lissette Gomez, Sami Heikkinen, Najaf Amin, Shahzad Ahmad, Seung Hoan Choi, Joshua Bis, Benjamin Grenier-Boley, Omar Garcia Rodriguez, Luca Kleineidam, et al.

    Due to methodological reasons, the X-chromosome has not been featured in the major genome-wide association studies on Alzheimer’s Disease (AD). To address this and better characterize the genetic landscape of AD, we performed an in-depth X-Chromosome-Wide Association Study (XWAS) in 115,841 AD cases or AD proxy cases, including 52,214 clinically-diagnosed AD cases, and 613,671 controls. We considered three approaches to account for the different X-chromosome inactivation (XCI) states in females, i.e. random XCI, skewed XCI, and escape XCI. We did not detect any genome-wide significant signals (P ≤ 5 × 10− 8) but identified seven X-chromosome-wide significant loci (P ≤ 1.6 × 10− 6). The index variants were common for the Xp22.32, FRMPD4, DMD and Xq25 loci, and rare for the WNK3, PJA1, and DACH2 loci. Overall, this well-powered XWAS found no genetic risk factors for AD on the non-pseudoautosomal region of the X-chromosome, but it identified suggestive signals warranting further investigations.


  • Open Access

    Novel early-onset Alzheimer-associated genes influence risk through dysregulation of glutamate, immune activation, and intracell signaling pathways

    by Carlos Cruchaga, Joseph Bradley, Daniel Western, Ciyang Wang, Eder Lucio Da Fonseca, Achal Neupane, Jiji Kurup, Nicholas Ray, Melissa Jean-Francois, Priyanka Gorijala, et al.

    Alzheimer Disease (AD) is a highly polygenic disease that presents with relatively earlier onset (≤70yo; EOAD) in about 5% of cases. Around 90% of these EOAD cases remain unexplained by pathogenic mutations. Using data from EOAD cases and controls, we performed a genome-wide association study (GWAS) and trans-ancestry meta-analysis on non-Hispanic Whites (NHW, NCase=6,282, NControl=13,386), African Americans (AA NCase=782, NControl=3,663) and East Asians (NCase=375, NControl=838 CO). We identified eight novel significant loci: six in the ancestry-specific analyses and two in the trans-ancestry analysis. By integrating gene-based analysis, eQTL, pQTL and functional annotations, we nominate four novel genes that are involved in microglia activation, glutamate production, and signaling pathways. These results indicate that EOAD, although sharing many genes with LOAD, harbors unique genes and pathways that could be used to create better prediction models or target identification for this type of AD


  • Open Access

    Human whole-exome genotype data for Alzheimer’s disease

    by Yuk Yee Leung, Adam C. Naj, Yi-Fan Chou, Otto Valladares, Michael Schmidt, Kara Hamilton-Nelson, Nicholas Wheeler, Honghuang Lin, Prabhakaran Gangadharan, Liming Qu, et al.

    The heterogeneity of the whole-exome sequencing (WES) data generation methods present a challenge to a joint analysis. Here we present a bioinformatics strategy for joint-calling 20,504 WES samples collected across nine studies and sequenced using ten capture kits in fourteen sequencing centers in the Alzheimer’s Disease Sequencing Project. The joint-genotype called variant-called format (VCF) file contains only positions within the union of capture kits. The VCF was then processed specifically to account for the batch effects arising from the use of different capture kits from different studies. We identified 8.2 million autosomal variants. 96.82% of the variants are high-quality, and are located in 28,579 Ensembl transcripts. 41% of the variants are intronic and 1.8% of the variants are with CADD > 30, indicating they are of high predicted pathogenicity. Here we show our new strategy can generate high-quality data from processing these diversely generated WES samples. The improved ability to combine data sequenced in different batches benefits the whole genomics research community.